Samuel C. Blackman Sells 10,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $16.02, for a total transaction of $160,200.00. Following the completion of the sale, the insider now directly owns 1,174,662 shares of the company’s stock, valued at approximately $18,818,085.24. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $16.64 on Wednesday. The firm has a market capitalization of $1.45 billion, a PE ratio of -6.99 and a beta of -1.48. Day One Biopharmaceuticals, Inc. has a 1 year low of $9.67 and a 1 year high of $17.85. The firm’s 50-day moving average is $15.27 and its two-hundred day moving average is $13.78.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings data on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Analysts expect that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current fiscal year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently modified their holdings of DAWN. SG Americas Securities LLC grew its stake in Day One Biopharmaceuticals by 58.7% during the 3rd quarter. SG Americas Securities LLC now owns 36,980 shares of the company’s stock worth $454,000 after purchasing an additional 13,683 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Day One Biopharmaceuticals by 22.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock valued at $2,703,000 after buying an additional 40,387 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Day One Biopharmaceuticals by 24.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company’s stock worth $535,000 after buying an additional 8,522 shares in the last quarter. TD Asset Management Inc increased its stake in shares of Day One Biopharmaceuticals by 100.0% during the third quarter. TD Asset Management Inc now owns 55,196 shares of the company’s stock worth $677,000 after buying an additional 27,598 shares during the period. Finally, Hennion & Walsh Asset Management Inc. raised its holdings in Day One Biopharmaceuticals by 89.5% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company’s stock valued at $660,000 after acquiring an additional 25,414 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. JPMorgan Chase & Co. upped their price objective on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Tuesday, February 27th. Finally, The Goldman Sachs Group lowered their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals has an average rating of “Moderate Buy” and an average target price of $39.83.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.